Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 4, Issue 2
  5. Article
Volume 4, Issue 2
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Recently, the scientific community has realized that COVID-19 effects are not limited to the acute period of infection but continue beyond that to cause more prolonged pathological changes. Post-COVID syndrome is a novel concept that describes the sequelae/persistent pathophysiological changes of post-COVID-19 infection. The current hypothesis suggests the involvement of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cardiac arrhythmias, coronary artery aneurism, acute renal injury, central nervous system degenerative diseases, vascular endothelial cell dysfunction, and pulmonary dyspnea, as well as fibrotic lung damage. Therefore, COVID-19 has been identified as a poly-syndromic and poly-systemic inflammatory disease. Post-COVID extrapulmonary complications have been observed in approximately 85% of hospitalized COVID-19 survivors and 35% of COVID-19 outpatients. Furthermore, 25% of hospitalised COVID-19 survivors developed myocardiopathy.

© 2023 Bentham Science Publishers
© 2023 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0250688204666230428120808
2023-07-18
2025-04-07

  • From This Site

    /content/journals/nemj/10.2174/0250688204666230428120808
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. CarfìA. BernabeiR. LandiF. Persistent symptoms in patients after acute COVID-19.JAMA2020324660360510.1001/jama.2020.1260332644129
     [Google Scholar]
  2. VojdaniA. VojdaniE. KharrazianD. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: Implications for autoimmune diseases.Front. Immunol.20211161708910.3389/fimmu.2020.61708933584709
     [Google Scholar]
  3. MaltezouH.C. PavliA. TsakrisA. Post-COVID syndrome: An insight on its pathogenesis.Vaccines20219549710.3390/vaccines905049734066007
     [Google Scholar]
  4. HalpinS. O’ConnorR. SivanM. Long COVID and chronic COVID syndromes.J. Med. Virol.20219331242124310.1002/jmv.2658733034893
     [Google Scholar]
  5. MahaseE. COVID-19: What do we know about “long covid”?BMJ202037010.1136/bmj.m2815
     [Google Scholar]
  6. WuQ. ZhouL. SunX. YanZ. HuC. WuJ. XuL. LiX. LiuH. YinP. LiK. ZhaoJ. LiY. WangX. LiY. ZhangQ. XuG. ChenH. Altered lipid metabolism in recovered SARS patients twelve years after infection.Sci. Rep.201771911010.1038/s41598‑017‑09536‑z28831119
     [Google Scholar]
  7. BilalogluS. AphinyanaphongsY. JonesS. IturrateE. HochmanJ. BergerJ.S. Thrombosis in hospitalized patients with COVID-19 in a New York City health system.JAMA2020324879980110.1001/jama.2020.1337232702090
     [Google Scholar]
  8. KlokF.A. KruipM.J.H.A. van der MeerN.J.M. ArbousM.S. GommersD.A.M.P.J. KantK.M. KapteinF.H.J. van PaassenJ. StalsM.A.M. HuismanM.V. EndemanH. Incidence of thrombotic complications in critically ill ICU patients with COVID-19.Thromb. Res.202019114514710.1016/j.thromres.2020.04.01332291094
     [Google Scholar]
  9. CuiS. ChenS. LiX. LiuS. WangF. CuiS. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.J. Thromb. Haemost.20201861421142410.1111/jth.1483032271988
     [Google Scholar]
  10. ShiS. QinM. ShenB. CaiY. LiuT. YangF. GongW. LiuX. LiangJ. ZhaoQ. HuangH. YangB. HuangC. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China.JAMA Cardiol.20205780281010.1001/jamacardio.2020.095032211816
     [Google Scholar]
  11. SiripanthongB. NazarianS. MuserD. DeoR. SantangeliP. KhanjiM.Y. CooperL.T.Jr ChahalC.A.A. Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management.Heart Rhythm20201791463147110.1016/j.hrthm.2020.05.00132387246
     [Google Scholar]
  12. AkhmerovA. MarbánE. COVID-19 and the Heart. Circulation Research.Lippincott Williams and Wilkins20201443145510.1161/CIRCRESAHA.120.317055
     [Google Scholar]
  13. BhatrajuP.K. GhassemiehB.J. NicholsM. KimR. JeromeK.R. NallaA.K. GreningerA.L. PipavathS. WurfelM.M. EvansL. KritekP.A. WestT.E. LuksA. GerbinoA. DaleC.R. GoldmanJ.D. O’MahonyS. MikacenicC. COVID-19 in critically ill patients in the seattle region — case series.N. Engl. J. Med.2020382212012202210.1056/NEJMoa200450032227758
     [Google Scholar]
  14. LiuP.P. BletA. SmythD. LiH. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation.Lippincott Williams and Wilkins2020687810.1161/CIRCULATIONAHA.120.047549
     [Google Scholar]
  15. ZhengY. Y. MaY. T. ZhangJ. Y. XieX. COVID-19 and the cardiovascular system.Nat. Rev. Cardiol.20201725926010.1038/s41569‑020‑0360‑5
     [Google Scholar]
  16. GuoT. FanY. ChenM. WuX. ZhangL. HeT. WangH. WanJ. WangX. LuZ. Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19).JAMA Cardiol.20205781181810.1001/jamacardio.2020.101732219356
     [Google Scholar]
  17. ZhouF. YuT. DuR. FanG. LiuY. LiuZ. XiangJ. WangY. SongB. GuX. GuanL. WeiY. LiH. WuX. XuJ. TuS. ZhangY. ChenH. CaoB. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study.Lancet2020395102291054106210.1016/S0140‑6736(20)30566‑332171076
     [Google Scholar]
  18. ChenT. WuD. ChenH. YanW. YangD. ChenG. MaK. XuD. YuH. WangH. WangT. GuoW. ChenJ. DingC. ZhangX. HuangJ. HanM. LiS. LuoX. ZhaoJ. NingQ. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.BMJ2020368m109110.1136/bmj.m109132217556
     [Google Scholar]
  19. LiuP.P. BletA. SmythD. LiH. The science underlying COVID-19.Circulation20201421687810.1161/CIRCULATIONAHA.120.04754932293910
     [Google Scholar]
  20. RajpalS. TongM.S. BorchersJ. ZarebaK.M. ObarskiT.P. SimonettiO.P. DanielsC.J. Cardiovascular magnetic resonance findings in competitive athletes recovering From COVID-19 infection.JAMA Cardiol.2021611161810.1001/jamacardio.2020.491632915194
     [Google Scholar]
  21. RichardsonS. HirschJ.S. NarasimhanM. CrawfordJ.M. McGinnT. DavidsonK.W. BarnabyD.P. BeckerL.B. ChelicoJ.D. CohenS.L. CookinghamJ. CoppaK. DiefenbachM.A. DominelloA.J. Duer-HefeleJ. FalzonL. GitlinJ. HajizadehN. HarvinT.G. HirschwerkD.A. KimE.J. KozelZ.M. MarrastL.M. MogaveroJ.N. OsorioG.A. QiuM. ZanosT.P. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.JAMA2020323202052205910.1001/jama.2020.677532320003
     [Google Scholar]
  22. ArentzM. YimE. KlaffL. LokhandwalaS. RiedoF.X. ChongM. LeeM. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State.JAMA2020323161612161410.1001/jama.2020.432632191259
     [Google Scholar]
  23. MyersL.C. ParodiS.M. EscobarG.J. LiuV.X. Characteristics of hospitalized adults With COVID-19 in an integrated health care system in California.JAMA2020323212195219810.1001/jama.2020.720232329797
     [Google Scholar]
  24. IshibashiY. YoneyamaK. TsuchidaT. J AkashiY. Post-COVID-19 postural orthostatic tachycardia syndrome.Intern. Med.20216014234510.2169/internalmedicine.7626‑2134053992
     [Google Scholar]
  25. NehmeM. BraillardO. AlcobaG. Aebischer PeroneS. CourvoisierD. ChappuisF. GuessousI. COVID-19 Symptoms: Longitudinal evolution and persistence in outpatient settings.Ann. Intern. Med.2021174572372510.7326/M20‑592633284676
     [Google Scholar]
  26. TenfordeM.W. KimS.S. LindsellC.J. Billig RoseE. ShapiroN.I. FilesD.C. GibbsK.W. EricksonH.L. SteingrubJ.S. SmithlineH.A. GongM.N. AboodiM.S. ExlineM.C. HenningD.J. WilsonJ.G. KhanA. QadirN. BrownS.M. PeltanI.D. RiceT.W. HagerD.N. GindeA.A. StubblefieldW.B. PatelM.M. SelfW.H. FeldsteinL.R. HartK.W. McClellanR. DoroughL. DzurisN. GriggsE.P. KassemA.M. MarcetP.L. OgokehC.E. SciarrattaC.N. SiddulaA. SmithE.R. WuM.J. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network-United States, March–June 2020.MMWR Morb. Mortal. Wkly. Rep.2020693099399810.15585/mmwr.mm6930e132730238
     [Google Scholar]
  27. StavemK. GhanimaW. OlsenM.K. GilboeH.M. EinvikG. Persistent symptoms 1.5–6 months after COVID-19 in non-hospitalised subjects: A population-based cohort study.Thorax202176440540710.1136/thoraxjnl‑2020‑21637733273028
     [Google Scholar]
  28. TaquetM. GeddesJ.R. HusainM. LucianoS. HarrisonP.J. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: A retrospective cohort study using electronic health records.Lancet Psychiatry20218541642710.1016/S2215‑0366(21)00084‑533836148
     [Google Scholar]
  29. ChopraV. FlandersS.A. O’MalleyM. MalaniA.N. PrescottH.C. O’MalleyM. MalaniA.N. PrescottH.C. O’MalleyM. MalaniA.N. Sixty-day outcomes among patients hospitalized with COVID-19.Ann. Intern. Med.2021174457657810.7326/M20‑566133175566
     [Google Scholar]
  30. ArnoldD.T. HamiltonF.W. MilneA. MorleyA.J. VinerJ. AttwoodM. NoelA. GunningS. HatrickJ. HamiltonS. ElversK.T. HyamsC. BibbyA. MoranE. AdamaliH.I. DoddJ.W. MaskellN.A. BarrattS.L. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: Results from a prospective UK cohort.Thorax202176439940110.1136/thoraxjnl‑2020‑21608633273026
     [Google Scholar]
  31. HalpinS.J. McIvorC. WhyattG. AdamsA. HarveyO. McLeanL. WalshawC. KempS. CorradoJ. SinghR. CollinsT. O’ConnorR.J. SivanM. Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation.J. Med. Virol.20219321013102210.1002/jmv.2636832729939
     [Google Scholar]
  32. JacobsL.G. Gourna PaleoudisE. Lesky-Di BariD. NyirendaT. FriedmanT. GuptaA. RasouliL. ZetkulicM. BalaniB. OgedegbeC. BawaH. BerrolL. QureshiN. AschnerJ.L. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection.PLoS One20201512e024388210.1371/journal.pone.024388233306721
     [Google Scholar]
  33. GarriguesE. JanvierP. KherabiY. Le BotA. HamonA. GouzeH. DoucetL. BerkaniS. OliosiE. MallartE. CorreF. ZarroukV. MoyerJ.D. GalyA. HonselV. FantinB. NguyenY. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19.J. Infect.2020816e4e610.1016/j.jinf.2020.08.02932853602
     [Google Scholar]
  34. HuangC. HuangL. WangY. LiX. RenL. GuX. KangL. GuoL. LiuM. ZhouX. LuoJ. HuangZ. TuS. ZhaoY. ChenL. XuD. LiY. LiC. PengL. LiY. XieW. CuiD. ShangL. FanG. XuJ. WangG. WangY. ZhongJ. WangC. WangJ. ZhangD. CaoB. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study.Lancet20213971027022023210.1016/S0140‑6736(20)32656‑833428867
     [Google Scholar]
  35. Carvalho-SchneiderC. LaurentE. LemaignenA. BeaufilsE. Bourbao-TournoisC. LaribiS. FlamentT. Ferreira-MaldentN. BruyèreF. SteficK. Follow-up of adults with noncritical COVID-19 two months after symptom onset.202127225826310.1016/j.cmi.2020.09.052
     [Google Scholar]
  36. MandalS. BarnettJ. BrillS.E. BrownJ.S. DennenyE.K. HareS.S. HeightmanM. HillmanT.E. JacobJ. JarvisH.C. LipmanM.C.I. NaiduS.B. NairA. PorterJ.C. TomlinsonG.S. HurstJ.R. ‘Long-COVID’: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19.Thorax202176439639810.1136/thoraxjnl‑2020‑21581833172844
     [Google Scholar]
  37. NalbandianA. SehgalK. GuptaA. MadhavanM.V. McGroderC. StevensJ.S. CookJ.R. NordvigA.S. ShalevD. SehrawatT.S. AhluwaliaN. BikdeliB. DietzD. Der-NigoghossianC. Liyanage-DonN. RosnerG.F. BernsteinE.J. MohanS. BeckleyA.A. SeresD.S. ChoueiriT.K. UrielN. AusielloJ.C. AcciliD. FreedbergD.E. BaldwinM. SchwartzA. BrodieD. GarciaC.K. ElkindM.S.V. ConnorsJ.M. BilezikianJ.P. LandryD.W. WanE.Y. Post-acute COVID-19 syndrome.Nat. Med.202127460161510.1038/s41591‑021‑01283‑z33753937
     [Google Scholar]
  38. LuJ. SunP.D. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity.J. Biol. Chem.202029552185791858810.1074/jbc.RA120.01530333122196
     [Google Scholar]
  39. AndersenK.G. RambautA. LipkinW.I. HolmesE.C. GarryR.F. The proximal origin of SARS-CoV-2.Nat. Med.202026445045210.1038/s41591‑020‑0820‑932284615
     [Google Scholar]
  40. Moreno-PérezO. MerinoE. Leon-RamirezJ.M. AndresM. RamosJ.M. Arenas-JiménezJ. AsensioS. SanchezR. Ruiz-TorregrosaP. GalanI. ScholzA. AmoA. González-delaAlejaP. BoixV. GilJ. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study.J. Infect.202182337838310.1016/j.jinf.2021.01.00433450302
     [Google Scholar]
  41. GuptaA. MadhavanM.V. SehgalK. NairN. MahajanS. SehrawatT.S. BikdeliB. AhluwaliaN. AusielloJ.C. WanE.Y. FreedbergD.E. KirtaneA.J. ParikhS.A. MaurerM.S. NordvigA.S. AcciliD. BathonJ.M. MohanS. BauerK.A. LeonM.B. KrumholzH.M. UrielN. MehraM.R. ElkindM.S.V. StoneG.W. SchwartzA. HoD.D. BilezikianJ.P. LandryD.W. Extrapulmonary manifestations of COVID-19.Nat. Med.20202671017103210.1038/s41591‑020‑0968‑332651579
     [Google Scholar]
  42. AmbardarS.R. HightowerS.L. HuprikarN.A. ChungK.K. SinghalA. CollenJ.F. Post-COVID-19 pulmonary fibrosis: Novel sequelae of the current pandemic.J. Clin. Med.20211011245210.3390/jcm1011245234205928
     [Google Scholar]
  43. KhouryM.K. GuptaK. FrancoS.R. LiuB. Necroptosis in the pathophysiology of disease.Am. J. Pathol.2020190227228510.1016/j.ajpath.2019.10.01231783008
     [Google Scholar]
  44. PuntmannV.O. CarerjM.L. WietersI. FahimM. ArendtC. HoffmannJ. ShchendryginaA. EscherF. Vasa-NicoteraM. ZeiherA.M. VehreschildM. NagelE. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19).JAMA Cardiol.20205111265127310.1001/jamacardio.2020.355732730619
     [Google Scholar]
  45. XuK. WeiY. GiuntaS. ZhouM. XiaS. Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?Exp. Gerontol.202115111142310.1016/j.exger.2021.11142334048906
     [Google Scholar]
  46. BikdeliB. MadhavanM.V. JimenezD. ChuichT. DreyfusI. DrigginE. NigoghossianC.D. AgenoW. MadjidM. GuoY. TangL.V. HuY. GiriJ. CushmanM. QuéréI. DimakakosE.P. GibsonC.M. LippiG. FavaloroE.J. FareedJ. CapriniJ.A. TafurA.J. BurtonJ.R. FranceseD.P. WangE.Y. FalangaA. McLintockC. HuntB.J. SpyropoulosA.C. BarnesG.D. EikelboomJ.W. WeinbergI. SchulmanS. CarrierM. PiazzaG. BeckmanJ.A. StegP.G. StoneG.W. RosenkranzS. GoldhaberS.Z. ParikhS.A. MonrealM. KrumholzH.M. KonstantinidesS.V. WeitzJ.I. LipG.Y.H. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up.J. Am. Coll. Cardiol.202075232950297310.1016/j.jacc.2020.04.03132311448
     [Google Scholar]
  47. VukusicK. ThorsellA. MuslimovicA. JonssonM. DellgrenG. LindahlA. SandstedtJ. HammarstenO. Overexpression of the SARS-CoV-2 receptor angiotensin converting enzyme 2 in cardiomyocytes of failing hearts.Sci. Rep.202212196510.1038/s41598‑022‑04956‑y35046458
     [Google Scholar]
  48. LindnerD. FitzekA. BräuningerH. AleshchevaG. EdlerC. MeissnerK. ScherschelK. KirchhofP. EscherF. SchultheissH.P. BlankenbergS. PüschelK. WestermannD. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases.JAMA Cardiol.20205111281128510.1001/jamacardio.2020.355132730555
     [Google Scholar]
  49. OuditG.Y. KassiriZ. JiangC. LiuP.P. PoutanenS.M. PenningerJ.M. ButanyJ. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS.Eur. J. Clin. Invest.200939761862510.1111/j.1365‑2362.2009.02153.x19453650
     [Google Scholar]
  50. MarzoogB.A. VlasovaT.I. The possible puzzles of BCG vaccine in protection against COVID-19 infection.Egypt. J. Bronchol.2021151710.1186/s43168‑021‑00052‑3
     [Google Scholar]
  51. MarzoogB.A. Recent advances in molecular biology of metabolic syndrome pathophysiology: Endothelial dysfunction as a potential therapeutic target.J. Diabetes Metab. Disord.20222121903191110.1007/s40200‑022‑01088‑y36065330
     [Google Scholar]
  52. MarzoogB.A. VlasovaT.I. Systemic and local hypothermia in the context of cell regeneration.Cryo Lett.2022432667310.54680/fr2221011011236626147
     [Google Scholar]
  53. MarzoogB.A. VlasovaT.I. Membrane lipids under norm and pathology.Eur J Clin Exp Med2021191597510.15584/ejcem.2021.1.9
     [Google Scholar]
  54. MarzoogB. Anticoagulant status under COVID-19: The potential pathophysiological mechanism.J App Hematol202213416710.4103/joah.joah_154_21
     [Google Scholar]
  55. MarzoogB.A. Coagulopathy and brain injury pathogenesis in post-COVID-19 syndrome.Cardiovasc. Hematol. Agents Med. Chem.202220317818810.2174/187152572066622040512402135382728
     [Google Scholar]
  56. MarzoogB. Lipid behavior in metabolic syndrome pathophysiology.Curr. Diabetes Rev.2022186e15092119649710.2174/157339981766621091510132134525924
     [Google Scholar]
  57. MarzoogB.A. VlasovaT.I. The metabolic syndrome puzzles; Possible pathogenesis and management.Curr. Diabetes Rev.20221810.2174/157339981866622042910041135507784
     [Google Scholar]
  58. MarzoogB.A. Tree of life: Endothelial cell in norm and disease, the good guy is a partner in crime!Anat. Cell Biol.2023Available at:10.5115/acb.22.190
     [Google Scholar]
  59. MarzoogB.A. Endothelial cell autophagy in the context of disease development.Anat. Cell Biol.2023561162410.5115/acb.22.09836267005
     [Google Scholar]
  60. MarzoogB.A. Transcription Factors-the essence of heart regeneration: A potential novel therapeutic strategy.Curr. Mol. Med.202223323223810.2174/156652402266622021612365035170408
     [Google Scholar]
  61. Abdullah MarzoogB. Autophagy as an anti-senescent in aging neurocytes.Curr. Mol. Med.202323epub ahead of print.10.2174/156652402366623012010271836683318
     [Google Scholar]
  62. MarzoogB.A. Local lung fibroblast autophagy in the context of lung fibrosis pathogenesis.Curr. Respir. Med. Rev.202319161110.2174/1573398X19666221130141600
     [Google Scholar]
  63. MarzoogB. A. Autophagy behavior in post-myocardial infarction injury.Cardiovasc Hematol Disord Drug Targets2023epub ahead of print.
     [Google Scholar]
  64. MarzoogB.A. VlasovaT.I. Myocardiocyte autophagy in the context of myocardiocytes regeneration: A potential novel therapeutic strategy.Egypt. J. Med. Hum. Genet.20222314110.1186/s43042‑022‑00250‑8
     [Google Scholar]
  65. MarzoogB.A. Autophagy in cancer cell transformation: A potential novel therapeutic strategy.Curr. Cancer Drug Targets202222974975610.2174/156800962266622042810274136062863
     [Google Scholar]
  66. SamiduraiA. DasA. Cardiovascular complications associated with COVID-19 and potential therapeutic strategies.Int. J. Mol. Sci.20202118679010.3390/ijms2118679032947927
     [Google Scholar]
  67. ChenL. LiX. ChenM. FengY. XiongC. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.Cardiovasc. Res.202011661097110010.1093/cvr/cvaa07832227090
     [Google Scholar]
  68. BozkurtB. KovacsR. HarringtonB. Joint HFSA/ACC/AHA statement addresses concerns re: Using RAAS antagonists in COVID-19.J. Card. Fail.202026537010.1016/j.cardfail.2020.04.01332439095
     [Google Scholar]
  69. VaduganathanM. VardenyO. MichelT. McMurrayJ.J.V. PfefferM.A. SolomonS.D. Renin–angiotensin–aldosterone system inhibitors in patients with COVID-19.N. Engl. J. Med.2020382171653165910.1056/NEJMsr200576032227760
     [Google Scholar]
  70. LopesR.D. MacedoA.V.S. de Barros E SilvaP.G.M. Moll-BernardesR.J. dos SantosT.M. MazzaL. FeldmanA. D’Andréa Saba ArrudaG. de AlbuquerqueD.C. CamilettiA.S. de SousaA.S. de PaulaT.C. GiustiK.G.D. DomicianoR.A.M. Noya-RabeloM.M. HamiltonA.M. LouresV.A. DionísioR.M. FurquimT.A.B. De LucaF.A. dos Santos SousaÍ.B. BandeiraB.S. ZukowskiC.N. de OliveiraR.G.G. RibeiroN.B. de MoraesJ.L. PetrizJ.L.F. PimentelA.M. MirandaJ.S. de Jesus AbufaiadB.E. GibsonC.M. GrangerC.B. AlexanderJ.H. de SouzaO.F. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted With COVID-19.JAMA2021325325426410.1001/jama.2020.2586433464336
     [Google Scholar]
  71. HumphreyT.J.L. JamesG. WittbrodtE.T. ZarzuelaD. HiemstraT.F. Adverse clinical outcomes associated with RAAS inhibitor discontinuation: Analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD)Clin. Kidney J.202114102203221210.1093/ckj/sfab02934804520
     [Google Scholar]
  72. KociolR.D. CooperL.T. FangJ.C. MoslehiJ.J. PangP.S. SabeM.A. ShahR.V. SimsD.B. ThieneG. VardenyO. Recognition and initial management of fulminant myocarditis.Circulation20201416e69e9210.1161/CIR.000000000000074531902242
     [Google Scholar]
/content/journals/nemj/10.2174/0250688204666230428120808
Loading
Pathophysiology of Cardiac Cell Injury in Post-COVID-19 Syndrome
NEW Emirates Medical J 4, e280423216351 (2023); https://doi.org/10.2174/0250688204666230428120808
/content/journals/nemj/10.2174/0250688204666230428120808
/content/journals/nemj/10.2174/0250688204666230428120808
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): ACE; Cardiology; Cardiovascular system; COVID-19; Pathogenesis; Pathophysiology; Post-COVID syndrome; RAAS; SARS-coV-2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test